PDT Partners’s Silk Road Medical, Inc. Common Stock SILK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-111,256
Closed -$3.01M 856
2024
Q2
$3.01M Buy
111,256
+219
+0.2% +$4.55K 0.28% 109
2024
Q1
$2.03M Sell
111,037
-34,270
-24% -$544K 0.19% 188
2023
Q4
$1.78M Buy
+145,307
New +$1.36M 0.2% 174
2023
Q2
Sell
-39,926
Closed -$1.56M 677
2023
Q1
$1.56M Buy
39,926
+9
+0% +$440 0.21% 171
2022
Q4
$2.11M Buy
39,917
+32,131
+413% +$1.56M 0.34% 75
2022
Q3
$350K Buy
+7,786
New +$335K 0.05% 537
2022
Q2
Sell
-26,455
Closed -$1.09M 1195
2022
Q1
$1.09M Sell
26,455
-10,430
-28% -$367K 0.09% 341
2021
Q4
$1.57M Sell
36,885
-16,820
-31% -$841K 0.12% 271
2021
Q3
$2.96M Buy
53,705
+3,887
+8% +$203K 0.21% 202
2021
Q2
$2.38M Buy
49,818
+40,832
+454% +$2.08M 0.16% 248
2021
Q1
$455K Buy
8,986
+681
+8% +$37.9K 0.03% 530
2020
Q4
$523K Buy
+8,305
New +$515K 0.04% 444
2020
Q2
Sell
-13,711
Closed -$432K 853
2020
Q1
$432K Buy
+13,711
New +$549K 0.03% 411

Other funds holding SILK

PDT Partners's SILK Position: Q3 2024 in Review

PDT Partners sold out of Silk Road Medical, Inc. Common Stock (SILK) in Q3 2024, closing a stake of 111,256 shares — an estimated $3.01M sold.

PDT Partners first reported a position in SILK in Q1 2020 and held it in 13 quarters. The position peaked at $3.01M in Q2 2024. 1 fund tracked by Wall St. Rank holds SILK as of Q3 2024.

  • PDT Partners reported no remaining Silk Road Medical, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • PDT Partners sold 111,256 Silk Road Medical, Inc. Common Stock shares in Q3 2024, an estimated $3.01M.
  • PDT Partners first reported a position in Silk Road Medical, Inc. Common Stock in Q1 2020 and held it in 13 quarters.
  • PDT Partners's Silk Road Medical, Inc. Common Stock position peaked at $3.01M in Q2 2024.
  • 1 fund tracked by Wall St. Rank held Silk Road Medical, Inc. Common Stock as of Q3 2024.

Based on PDT Partners's 13F filing for Q3 2024, filed 14 Nov 2024.